Navigation Links
New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
Date:10/24/2007

which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 1 study of RDEA119 in patients with advanced cancer in the fourth quarter of 2007, evaluating RDEA119 for inflammatory diseases next year, and initiating clinical studies on three additional compounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Blurb shows that print still captures imaginations
2. Kauffman study shows consistent entrepreneurial growth
3. Directory shows high-tech growth spurt in Dane Co.
4. Stem cell therapy shows visionary promise
5. TDS restates years of revenues, shows slight profit drop
6. As BIO shows mass of competition, hunt for partners is on
7. UW shows why avian flu hasnt spread among humans yet
8. NameProtect study shows 92% of top brands losing out on search engines
9. Stem cell breakthrough by UW shows why federal research should be broadened
10. Student survey shows surging demand for wireless access
11. Wisconsins tech employment shows increase, HR firm reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
(Date:12/24/2014)... The report provides basic information ... application and industry overview. This report also presents ... Production is separated by regions, technology and applications. ... downstream client survey, marketing channels, industry development trend ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... the future will utilise technologies not currently available. An ... carbon nanotubes as interconnects for computer chips. This is ... work from nanotechnology researchers within the Materials Ireland Polymer ... work to develop such junction structure nanotubes used various ...
... DIEGO, Nov. 21 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... 19th Annual,Piper Jaffray Healthcare Conference on Tuesday, November 27, ... is being held at the Pierre Hotel,in New York., ... of Anadys,Pharmaceuticals, Inc., will present an overview of Anadys ...
... SOUTH SAN FRANCISCO, Calif., Nov. 21 ,Exelixis, Inc. (Nasdaq: ... the company,s president and chief executive officer will present ... 1:00 p.m.,ET / 10:00 a.m. PT on Wednesday, November ... may be accessed in the Event,Calendar page under Investors ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 The ... it easier to detect and prevent counterfeit microcircuits from ... agency started performing an in-house microcircuit anti-counterfeit initiative dubbed ... purchased microcircuits while increasing their reliability throughout the supply ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... tetrachloroethylene (PCE) -- found to have contaminated drinking water ... to 1985 have been linked to certain diseases and ... the National Research Council, Contaminated Water Supplies at Camp ... about the potential adverse health effects that could occur ...
... b3c newswire / - Dutch biotechnology company ... Scientific Research TNO today announced that they have entered ... viral gene delivery platform SVac . Under this agreement, ... and testing of viral gene delivery systems such as ...
... Society for Microbiology (ASM) Siemens Healthcare Diagnostics ... Melissa B. Miller, Ph.D., D(ABMM), director, Clinical ... Pathology and Laboratory Medicine, and associate director, ... North Carolina (UNC) School of Medicine, Chapel ...
Cached Biology News:Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 3
... Smart Minis 300V power supply (Cat. No. ... voltage, sufficient for SDS-PAGE, and native PAGE ... pairs of terminator pairs can be used ... for individuals to have his/her own power ...
... dedicated imaging system for detection of very ... pixel size. Equipped with an extreme sensitive ... animals or plants in tumor research, infectious ... Western blots. NightOWL is the only imager ...
... NovaTaq DNA Polymerase is a premium quality ... This thermostable enzyme is suitable for a ... the highest purity and reproducible performance, each ... of quality control assays. NovaTaq DNA Polymerase ...
... BD FACSAria cell sorter sets a new ... Based on a revolutionary new design in ... sorting and multicolor analysis. The BD FACSAria ... incorporates a fixed-alignment cuvette flow cell. ...
Biology Products: